scholarly journals Investigation of Metal-Organic Framework-5 (MOF-5) as an Antitumor Drug Oridonin Sustained Release Carrier

Molecules ◽  
2019 ◽  
Vol 24 (18) ◽  
pp. 3369 ◽  
Author(s):  
Gongsen Chen ◽  
Juyuan Luo ◽  
Mengru Cai ◽  
Liuying Qin ◽  
Yibo Wang ◽  
...  
Keyword(s):  
Sustained Release ◽  
Anticancer Activity ◽  
Hepg2 Cells ◽  
Metal Organic Framework ◽  
Drug Carrier ◽  
Drug Loading ◽  
Addition Method ◽  
Direct Addition ◽  
Metal Organic ◽  
Organic Framework

Oridonin (ORI) is a natural active ingredient with strong anticancer activity. But its clinical use is restricted due to its poor water solubility, short half-life, and low bioavailability. The aim of this study is to utilize the metal organic framework material MOF-5 to load ORI in order to improve its release characteristics and bioavailability. Herein, MOF-5 was synthesized by the solvothermal method and direct addition method, and characterized by Scanning Electron Microscopy (SEM), X-Ray Diffraction (XRD), Fourier Transform Infrared Spectrometer (FTIR), Thermogravimetric Analysis (TG), Brunauer–Emmett–Teller (BET), and Dynamic Light Scattering (DLS), respectively. MOF-5 prepared by the optimal synthesis method was selected for drug-loading and in vitro release experiments. HepG2 cells were model cells. MTT assay, 4′,6-diamidino-2-phenylindole (DAPI) staining and Annexin V/PI assay were used to detect the biological safety of blank carriers and the anticancer activity of drug-loaded materials. The results showed that nano-MOF-5 prepared by the direct addition method had complete structure, uniform size and good biocompatibility, and was suitable as an ORI carrier. The drug loading of ORI@MOF-5 was 52.86% ± 0.59%. The sustained release effect was reliable, and the cumulative release rate was about 87% in 60 h. ORI@MOF-5 had significant cytotoxicity (IC50:22.99 μg/mL) and apoptosis effect on HepG2 cells. ORI@MOF-5 is hopeful to become a new anticancer sustained release preparation. MOF-5 has significant potential as a drug carrier material.

Nontoxic and renewable metal–organic framework based on α-cyclodextrin with efficient drug delivery

RSC Advances ◽  
2016 ◽  
Vol 6 (86) ◽  
pp. 82977-82983 ◽  
Author(s):  
Jing-Quan Sha ◽  
Xiao-Hua Zhong ◽  
Lian-He Wu ◽  
Guo-Dong Liu ◽  
Ning Sheng
Keyword(s):  
Drug Delivery ◽  
Sustained Release ◽  
Metal Organic Framework ◽  
Drug Loading ◽  
Loading Capacity ◽  
Left Handed ◽  
Metal Organic ◽  
Organic Framework

Two new nontoxic α-CD based compounds were synthesized by different method, which contain different left-handed helix and exhibit efficient drug loading capacity and sustained release behaviors.

Improving the genistein oral bioavailability via its formulation into the metal–organic framework MIL-100(Fe)

2021 ◽  
Vol 9 (9) ◽  
pp. 2233-2239
Author(s):  
Adrià Botet-Carreras ◽  
Cristina Tamames-Tabar ◽  
Fabrice Salles ◽  
Sara Rojas ◽  
Edurne Imbuluzqueta ◽  
...  
Keyword(s):  
Oral Bioavailability ◽  
Metal Organic Framework ◽  
Drug Carrier ◽  
Aqueous Solubility ◽  
Carrier System ◽  
System P ◽  
Metal Organic ◽  
Drug Carrier System ◽  
Organic Framework

Despite the interesting chemopreventive, antioxidant and antiangiogenic effects of the natural bioflavonoid genistein (GEN), its low aqueous solubility and bioavailability make it necessary to administer it using a suitable drug carrier system.

scholarly journals Histidine polypeptide-hybridized nanoscale metal–organic framework to sense drug loading/release

2021 ◽  
Vol 205 ◽  
pp. 109741
Author(s):  
Yanan Xu ◽  
Zhenhua Li ◽  
Dan Xiu ◽  
Guotao Sun ◽  
Christopher D. Snow ◽  
...  
Keyword(s):  
Metal Organic Framework ◽  
Drug Loading ◽  
Metal Organic ◽  
Organic Framework

Mesoporous metal–organic framework MIL-100(Fe) as drug carrier

Adsorption ◽  
2021 ◽  
Author(s):  
Paulo G. M. Mileo ◽  
Diony N. Gomes ◽  
Daniel V. Gonçalves ◽  
Sebastião M. P. Lucena
Keyword(s):  
Metal Organic Framework ◽  
Drug Carrier ◽  
Metal Organic ◽  
Mesoporous Metal ◽  
Organic Framework

Preparation of a one-dimensional nanorod/metal organic framework Janus nanoplatform via side-specific growth for synergistic cancer therapy

2019 ◽  
Vol 7 (4) ◽  
pp. 1696-1704 ◽  
Author(s):  
Haipeng Zhang ◽  
Qin Zhang ◽  
Chunshui Liu ◽  
Bing Han
Keyword(s):  
Cancer Therapy ◽  
Specific Growth ◽  
Metal Organic Framework ◽  
Drug Loading ◽  
Ct Image ◽  
One Dimensional ◽  
Image Guided ◽  
Metal Organic ◽  
Organic Framework

A unique LA-AuNR/ZIF-8 Janus nanoparticle is firstly prepared by side-specific growth of ZIF-8 on one-dimensional AuNR for drug loading to realize the CT image-guided active targeted synergistic chemo-photothermal cancer therapy.

One-pot synthesis of a metal–organic framework-based drug carrier for intelligent glucose-responsive insulin delivery

2018 ◽  
Vol 54 (42) ◽  
pp. 5377-5380 ◽  
Author(s):  
Yan Duan ◽  
Fanggui Ye ◽  
Yuanlin Huang ◽  
Yuemei Qin ◽  
Caimei He ◽  
...  
Keyword(s):  
Metal Organic Framework ◽  
Drug Carrier ◽  
Insulin Delivery ◽  
Glucose Stimulation ◽  
One Pot ◽  
One Pot Synthesis ◽  
Metal Organic ◽  
Organic Framework

A glucose-responsive metal–organic framework (MOF)-based insulin delivery nanosystem was developed via a one-pot process. The system relies on the MOF response to glucose stimulation and this can promote insulin delivery.

scholarly journals In Vitro Toxicity Study of a Porous Iron(III) Metal‒Organic Framework

Molecules ◽  
2019 ◽  
Vol 24 (7) ◽  
pp. 1211 ◽  
Author(s):  
Gongsen Chen ◽  
Xin Leng ◽  
Juyuan Luo ◽  
Longtai You ◽  
Changhai Qu ◽  
...  
Keyword(s):  
Metal Organic Framework ◽  
Drug Carrier ◽  
In Vitro Cytotoxicity ◽  
In Vitro Toxicity ◽  
Porous Iron ◽  
Dapi Staining ◽  
Toxicological Assessment ◽  
Metal Organic ◽  
Organic Framework

A MIL series metal‒organic framework (MOF), MIL-100(Fe), was successfully synthesized at the nanoscale and fully characterized by TEM, TGA, XRD, FTIR, DLS, and BET. A toxicological assessment was performed using two different cell lines: human normal liver cells (HL-7702) and hepatocellular carcinoma (HepG2). In vitro cytotoxicity of MIL-100(Fe) was evaluated by the MTT assay, LDH releasing rate assay, DAPI staining, and annexin V/PI double staining assay. The safe dose of MIL-100(Fe) was 80 μg/mL. It exhibited good biocompatibility, low cytotoxicity, and high cell survival rate (HL-7702 cells’ viability >85.97%, HepG2 cells’ viability >91.20%). Therefore, MIL-100(Fe) has a potential application as a drug carrier.

Sign in / Sign up

Export Citation Format

Share Document